

CURRICULUM VITAE

LELAND J. FOSHAG, M.D., F.A.C.S.

PERSONAL

Born: Van Nuys, California

CITIZENSHIP

United States

EDUCATION

1969 – 1972 Bachelor's Degree, Biology / Chemistry
Vanderbilt University
Nashville, TN

1972 – 1975 Medical Degree
Ohio State University
College of Medicine
Columbus, OH

POSTGRADUATE TRAINING

1975 – 1976 Internship-Surgery
Vanderbilt University
Nashville, TN

1976 – 1978 Junior Resident-Surgery
Vanderbilt University
Nashville, TN

1978 – 1980 Junior Resident-Surgery
West Virginia University
Morgantown, W. VA

1980 – 1981 Chief Resident-Surgery
West Virginia University
Morgantown, W.VA

CERTIFICATION

1976 Diplomat, National Board of Medical Examiners

1983 Diplomat, American Board of Surgery (Issued 12/14/1983)

1993 Re-Certification, American Board of Surgery (Re-issued 10/22/1993)

1993 X-ray Supervisor & Operator Certificate / Permit

1997 Re-Certification, X-ray Supervisor & Operator Certificate / Permit

APPOINTMENTS

1981 – 1984 Assistant Professor of Surgery
Department of Surgery
West Virginia University
Morgantown, W.VA

1984 – 1987 Associate Professor of Surgery
Department of Surgery
West Virginia University
Morgantown, W.VA

1981 – 1987 Attending Surgeon
VA Medical Center
Clarksburg, W.VA

1987 – 1989 Adjunct Assistant Clinical Professor
Division of Surgical Oncology
UCLA, Los Angeles, CA

1988 – 1991 Attending Surgeon
UCLA Medical Center
Los Angeles, CA

1989 – 1991 Assistant Professor of Clinical Surgery (compensated)
Division of Surgical Oncology
UCLA Medical Center, Los Angeles, CA

1994 – 1997 Attending Surgeon
UCLA Medical Center
Los Angeles, CA

1991 – 1997 Assistant Clinical Professor
Division of Surgical Oncology
UCLA Medical Center
Los Angeles, CA

1991 – Present Associate Director
John Wayne Cancer Institute
Santa Monica, CA

1991 – Present Active Staff, Saint John's Health Center
Santa Monica, CA

1994 – Present Active Staff, Century City Hospital
Los Angeles, CA

1994 – Present Active Staff, Good Samaritan Hospital
Los Angeles, CA

1995 – Present Voluntary Faculty, Assistant Clinical Professor
USC, Los Angeles, CA

1996 – Present Active Staff, Orthopaedic Hospital
Los Angeles, CA

ADMINISTRATIVE APPOINTMENTS

1989 – 1990 Committee Member, Utilization Review
UCLA Medical Center
Los Angeles, CA

1989 – 1991 Associate Member, Jonsson Comprehensive Cancer Center
UCLA Medical Center
Los Angeles, CA

1991 – Present Director of Pancreatic Research
John Wayne Cancer Institute
Santa Monica, CA

1991 – Present Director of Clinical Pancreatic Cancer Service
Saint John's Health Center
Santa Monica, CA

1991 – 1999 IRB Research Committee
Saint John's Health Center
Santa Monica, CA

1991 – 2002 Cancer Committee
Saint John's Health Center
Santa Monica, CA

1993 – 2002 Cancer Committee Chairman
Saint John's Health Center
Santa Monica, CA

1992 – 2002	Liaison Physician for Commission on Cancer American College of Surgeons Representing Saint John's Health Center
1992 – 1993	Master Site Planning Committee Saint John's Health Center Santa Monica, CA
1993 – 1994	Search Committee for Medical Director of Pathology Saint John's Health Center Santa Monica, CA
1996 – 1998	IROC Chairman John Wayne Cancer Institute Santa Monica, CA
1997 – 2000	Protocol Review Monitor Committee John Wayne Cancer Institute Santa Monica, CA
1996 – Present	Cancer Committee Orthopaedic Hospital Los Angeles, CA
1996 – Present	Education Committee Orthopaedic Hospital Los Angeles, CA
1999 – Present	Assistant Director The Cancer Center at Century City Hospital Los Angeles, CA

HOSPITAL AFFILIATIONS

1991 – Present	Saint John's Health Center, Santa Monica, CA
1994 – Present	Century City Hospital, Los Angeles, CA
1994 – Present	Good Samaritan Hospital, Los Angeles, CA
1996 – Present	Orthopaedic Hospital, Los Angeles, CA

FELLOWSHIPS

- 1977 – 1977 Resident Research Fellowship, S.R. Light Laboratory
Vanderbilt, University, TN
Richard Dean, M.D., Program Director
- 1984 – 1984 Two-month Fellowship, Head & Neck Surgery
Roswell Park Memorial Institute, NY
Daniel P. Shedd, M.D., Program Director
- 1987 – 1989 Research Fellow, Division of Surgical Oncology
UCLA Medical Center, CA
Donald L. Morton, M.D., Program Director

AWARDS

- 1980 - 1981 West Virginia University
Resident Teaching Award
- 1982 – 1983 West Virginia University
Faculty Teaching Award
- 1987 – 1990 National Science Research Award

PROFESSIONAL SOCIETIES

- 1981 - Present West Virginia State Medical Association
- 1984 – 1987 Southeastern Surgical Congress
- 1982 – Present Association of Academic Surgeons
- 1985 – Present Fellow, American College of Surgeons
- 1992 – Present The Society of Surgical Oncology
- 1993 – Present American Association for Cancer Research
- 1994 – Present American Society of General Surgeons
- 1994 – Present American Society of Clinical Oncology
- 1995 – Present Society of Head & Neck Surgeons

NATIONAL COOPERATIVE GROUPS

- 1985 – 1987 National Surgical Adjuvant Breast & Bowel Project
Co-Investigator
- 1986 – 1987 Eastern Oncology Cooperative Group

GRANT SUPPORT

- **Principal Investigator** Multicenter Phase III Trial to Evaluate the Efficacy of Recombinant Human GM-CSF for Prophylaxis of Post-Operative Infection. *Immunex Research & Development Corporation*
- **Co-Investigator** Surgery, Immunology, and Immunotherapy of Human Cancer. *National Cancer Institute (CA 12582)*
- **Co-Investigator** New Approaches to Surgical Oncology *National Cancer Institute (CA 29605)*
- **Co-Investigator** Molecular Assay to Detect Hematogenous Breast Cancer Metastases. *U.S. Army Breast Cancer Research Program*
- **Co-Investigator** Polyvalent Vaccine Phase III Trial in Stage IV Melanoma. *National Cancer Institute*
- **Co-Investigator** Polyvalent Vaccine Phase III Trial Stage III Melanoma. *National Cancer Institute*

BIBLIOGRAPHY

JOURNAL ARTICLES

1. Dean RH, Polerhauer P, **Foshag LJ**. et al. Effect of total portal diversion on lipid synthesis. *Surg Forum* 29:447-449, 1978.
2. McDowell DE, **Foshag LJ**. Ergotism treated with nitroprusside. *Contemp Surg* 19:100-106, 1980.
3. Liza EF, Elydrani MK, **Foshag LJ**, Boyd CB, Belis JA. Chronic fistula developing two years after nephrectomy for pyonephrosis. *J Urol*, April 1983.
4. Vasiloff J, Chideckel EW, Boyd CB, **Foshag LJ**. Testosterone secreting adrenal adenoma containing crystalloids characteristic of leydig cells. *Am J Med* 70:772-776, 1985.
5. Biggs T, **Foshag LJ**, Vargish T, Zimmerman B. Biliary tract injuries following cholecystectomy. *Am Surg* 52:312-314, 1986.
6. Dowling K, Watne A, **Foshag LJ**, Vargish T. The management of non-familial

- adenomatous polyps and colon cancer. *Surgery* 98:684-688, 1985.
7. Al-Kawas FH, Murgo A, **Foshag LJ**, Shiels W. Lymphadenectomy in celiac disease not always a sign of lymphoma. *Am J Gastroenterol* 83:301-303, 1988.
 8. **Foshag LJ**, Watne A. Head and neck nodules. *Prob Gen Surg* 5(1): 50-57, 1988.
 9. Morton DL, **Foshag LJ**, Nizze JA, Gupta RK, Famatiga E, Hoon DSB, Irie RF. Active specific immunotherapy in malignant melanoma. *Semin Surg Oncol* 5:420-425, 1989.
 10. Kopald KH, Layfiel LJ, Mohrmann R, **Foshag LJ**, Giuliano AE. Clarifying the role of fine needle aspiration cytology and frozen section examination in the operative management of thyroid cancer. *Arch Surg* 124:1201-1205, 1989.

PRESENTATIONS AND PUBLISHED ABSTRACTS

1. Watne A, **Foshag LJ**, Dowling K, Koike A, Suzamera T, Kanemitsu T. The relationship of adenomatous polyps to metachronous colon cancer: A comparison of the American and Japanese patients. *UICC Proceedings, Budapest, Hungary August 1986*.
2. **Foshag LJ (Presenter)**, Hoon DSB, Niku SD, Chang LC, Nizze A, Morton DL. Immunoregulation of IgM synthesis by peripheral mononuclear cells (PBL) from melanoma cell vaccine (MCV). Patients with thymosin fraction 5 (TF5) and Alpha-1 (TAL). *American Association of Immunology, Fed Proc* 2, 1988.
3. Hoon DSB, Niku SD, Morton DL, Chang LC, Dajac R, Nizze A, **Foshag LJ**. Immunomodulation with thymosin fraction 5 (TF5) and Alpha-1 (Tal) on peripheral blood mononuclear cells (PBL) from patients receiving active specific immunotherapy melanoma cell vaccine. *Proc Am Assoc Cancer Res.* 29:413, 1988.
4. Hoon DSB, **Foshag LJ**, Gregorio E, Nizze A, Morton DL. A randomized trial of immunomodulation with various low dosages of cyclophosphamide in patients receiving active specific immunotherapy with melanoma cell vaccine. *Proc Am Assoc Cancer Res.* 29:413, 1988.
5. **Foshag LJ (Presenter)**, Hoon DSB, Niku SD, Chang LC, Nizze A, Morton DL. Immunomodulation of IgG synthesis by peripheral mononuclear cells from melanoma cell vaccine patients with thymosin. *Proc Am Assoc Cancer Res* 29:411, 1988.
6. **Foshag LJ (Presenter)**, Hoon DSB, Niku SD, Chang LC, Nizze A, Morton DL.

- Immunoregulation of IgM synthesis by peripheral mononuclear cells (PBL) from melanoma cell vaccine (MCV) patients with thymosin fraction 5 (TF5) and Alpha-1 (T1). *Am Assoc Immunol, Fed Proc 2, 1988.*
7. Hoon DSB, Niku SD, Morton DL, Chang CL, Dajac R, Nizze A, **Foshag LJ**. Immunomodulation with thymosin fraction V (TF5) and Alpha-1 (T1) on peripheral blood mononuclear cells (PBL's) from patients receiving active specific immunotherapy with melanoma cell vaccine (MCV). *Am Assoc Immunol, Fed Proc 2, 1988.*
 8. Morton DL, Hoon DSB, **Foshag LJ**, Nizze A. Melanoma associated antigen antibody responses in a trial of immunomodulation with various low dosages of cyclophosphamide in patients receiving active specific immunotherapy with melanoma cell vaccine. *Proc Am Assoc Cancer Res 29:399, 1988.*
 9. Morton DL, Hoon DSB, **Foshag LJ**, Nizze A, Furatani S, Famatiga E. Clinical results of a trial of immunotherapy with melanoma cell vaccine (MCV) plus biological response modifiers (BRM). *7th Int. Congress Immunology, #106-66:757, July 1989.*
 10. Hoon DSB, **Foshag LJ**, Okun E, Morton DL. Specific antibody and cellular immune response in melanoma patients receiving active specific immunotherapy with melanoma cell vaccine (MCV). *7th Int. Congress Immunology #106-34:752, July 1989.*
 11. Morton DL, Hoon D, **Foshag LJ**, Nizze A, Famatiga E, Gupta R, Irie R. Clinical results of a trial of active specific immunotherapy with melanoma cell vaccine (MCV) and immunomodulation in metastatic melanoma. *2nd International Conference on Melanoma-Venice, Italy 1989.*
 12. Hoon DSB, **Foshag LJ**, Morton DL. Immunomodulation of antibody production by biological response modifiers (BRM). *Proc Am Assoc Cancer Res 30:383, 1989.*
 13. **Foshag LJ (Presenter)**, Hoon DSB, Okun E, Nizze A, Morton DL. Specific cell-mediated cytotoxicity in melanoma patients receiving melanoma cell vaccine (MCV) in combination with various biological response modifiers (BRM). *Proc Am Assoc Cancer Res 30:344, 1989.*
 14. Morton DL, Hoon D, Nizze A, Foshag LJ, Gupta R, Irie R. Active specific immunotherapy with melanoma cell vaccine (MCV) and immunomodulation in patients with metastatic melanoma. *Proceedings of the International Conference on Biological Treatment of Melanoma and other Cancers. New South Wales, September, 1990.*

15. **Foshag LJ (Presenter)**, Hoon DSB, Okun E, Nizze JA, Morton DL. T-Cell cytotoxicity in melanoma patients receiving active specific immunotherapy for melanoma and clinical correlation outcome. *Surgical Forum, American College of Surgeons, San Francisco, October 1990.*
16. Hoon DSB, **Foshag LJ**, Nizze JA, Bohman R, Morton DL. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. *Cancer Res 50:5358-5364, 1990.*
17. **Foshag LJ**, Hoon DSB, Okun E, Nizze JA, Morton DL. T-Cell cytotoxicity in patients receiving active specific immunotherapy for melanoma and correlation to clinical outcome. *Surg. Forum 41:430-431, 1990.*
18. Gutierrez D, Hoon D, **Foshag LJ**, Gupta R, Morton D. Enhancement of melanoma associated antigen antibodies by melanoma patients' lymphocytes in-vitro by Interleukins 2, 4, 6, or 7. *Proc Am Assoc Cancer Res 31:241, 1990.*
19. **Foshag LJ (Presenter)**, Hoon D, Park M, Terasaki P, Morton D. HLA Class I antigen expression by melanoma and the immune response in patients with allogenic immunization. *Proc Am Assoc Cancer Res 31:281, 1990.*
20. Hoon D, **Foshag LJ**, Nizze A, Okun E, Morton DL. Mixed lymphocyte tumor reaction and delayed type hypersensitivity in patients receiving specific immunotherapy. *Proc Am Assoc Cancer Res 31-253, 1990.*
21. Morton DL, Nizze A, **Foshag LJ**, Hoon D, Famatiga E, Gupta R, Irie R. Long term survival in metastatic melanoma after active specific immunotherapy with melanoma cell vaccine (MCV) and immunomodulation. *Proc Am Assoc Cancer Res 31:281, 1990.*
22. Morton DL, Wen D, Economou J, Wong J, **Foshag LJ**, Cochran A. Intraoperative lymphatic mapping and selective lymphadenectomy: Technical details of a new procedure for clinical Stage I (CS-I) melanoma. *Society of Surgical Oncology, 1990.*
23. Morton DL, Hoon DSB, **Foshag LJ**, Nizze JA, Gupta R, Famatiga E, Irie RF. Active specific immunotherapy of metastatic melanoma with melanoma vaccine and immunomodulation. *Proc Am Assoc Cancer Res 32:492, 1991.*
24. Wong JH, Xu SH, Skinner KA, **Foshag LJ**, Morton DL. Prospective evaluation of the use of antigen specific immune complexes in predicting the development of recurrent melanoma. *Surg Forum 126:1450-1454, 1991.*

25. Wong JH, Xu SH, Skinner KA, **Foshag LJ**, Morton DL. Prospective evaluation of the utility of antigen specific immune complexes in detecting recurrent melanoma. *Society of Surgical Oncology, 1991.*
26. **Foshag LJ (Presenter)**, Hoon DSB, Nizze JA, Wong JH, Morton DL. Effect of low dose cyclophosphamide and humoral immune response in a randomized trial given in conjunction with acute immunotherapy. *Society of Surgical Oncology, 1991.*
27. Morton DL, Hoon D, Nizze A, **Foshag LJ**, Gupta R, Irie R. Active specific immunotherapy with melanoma cell vaccine (MCV) and immunomodulation in patients with metastatic melanoma. *Proc Am Soc Clin Oncol 10:295, 1991.*
28. Morton DL, Wen DR, Cochran AJ, **Foshag LJ**, Essner R. Intraoperative lymphatic mapping for early stage melanoma of the head and neck. *Proceedings of the Third International Conference on Head and Neck Cancer, Elsevier, Amsterdam, 1992.*
29. Morisaki T, Yuzuki D, Lin R, **Foshag LJ**, Morton DL, Hoon DSB. Interleukin 4 receptor expression and growth inhibition of gastric carcinoma cells by Interleukin 4. *Cancer Res 52:6059-6065, 1992.*
30. Guenther JM, **Foshag LJ**, Wanek LA, Morton DL. Low incidence of melanoma recurrence beyond ten years. *Oral Presentation, Society of Surgical Oncology, Los Angeles, CA-USA, March 18-21, 1993.*
31. Tafra L, **Foshag LJ**, Morton DL. Long-term survivors of melanoma metastatic to distant sites. *Society of Surgical Oncology, Los Angeles, CA March 18-21, 1993.*
32. Morton DL, Nizze A, Hoon D, **Foshag LJ**, Famatiga E, Gupta R, Irie R, Ramming K. Improved survival of advanced Stage IV melanoma following active immunotherapy: Correlation with immune responses to melanoma vaccine. *Proc Am Soc Clin Oncol 12:391, 1993*
33. **Foshag LJ (Presenter)**, Morton DL, Nizze JA, Chawla SP. Response to chemotherapy in melanoma patients after active specific immunotherapy (ASI) with melanoma cell vaccine (MCV). *Proc Am Soc Clin Oncol 12:396, 1993.*
34. Wong JH, Skinner KA, Kim KA, **Foshag LJ**, Morton DL. The role of surgery in the treatment of nonregionally recurrent melanoma. *Surgery 1993; 113:389-394*
35. Guenther JM, Kirgan D, Klein R, **Foshag LJ**, Ramming K. Coagulopathy associated with cryosurgery for hepatic metastases of colorectal cancer. *Proc Am Soc Clin Oncol 13:213, 1994.*

36. Guenther JM, Kirgan DM, **Foshag LJ**, Ramming KP. Cryosurgical ablation of metastatic neuroendocrine tumors. *American College of Surgeons, 1994.*
37. Guenther J, Kirgan D, Klein R, **Foshag L**, Ramming K. Coagulopathy associated with cryosurgery for hepatic metastases of colorectal cancer. *Proc Am Soc Clin Oncol 1994;13:213.*
38. Dale PS, **Foshag LJ**, Wanek LA, Morton DL. Prognosis of melanoma patients with metastases to two separate lymph node basins. *Poster Presentation, Society of Surgical Oncology, Houston, TX-USA, March 17-20, 1994.*
39. Essner R, **Foshag LJ**, Cochran AJ, Wen DR, Stern S, Wanek LA, Conforti A, Morton DL. Intraoperative lymphatic mapping and selective lymphadenectomy in 481 patients with early-stage melanoma. *Oral Presentation, American College of Surgeons Clinical Congress, San Francisco, CA, October 8-8, 1996.*
40. Bostick P, Sarantou T, Essner R, Kelley M, Glass E, **Foshag LJ**, Morton DL. Intraoperative lymphatic mapping for early-stage melanoma of the head and neck. *Society of Head and Neck Surgeons, Cancun, Mexico, April 10-12, 1997.*
41. Bilchik AJ, Sarantou T, **Foshag LJ**, Giuliano AE, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. *Surgery 1997;122:1040-1047.*
42. Dale PS, **Foshag LJ**, Wanek LA, Morton DL. Metastasis of primary melanoma to two separate lymph node basins: prognostic significance. *Ann Surg Oncol 1997;4(1):13-18.*
43. Kelley MC, Bostick P, Bilchik A, **Foshag LJ**, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB. Molecular detection of pancreatic carcinoma (PC) with a multiple marker RT-PCR assay. *Proc Am Soc Clin Oncol 1997; 16:293a.*
44. Hsueh EC, Nizze JA, Essner R, **Foshag LJ**, Famatiga E, Stern SL, Morton DL. Adjuvant immunotherapy with polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant metastases: Matched pair analysis. *Proc Am Soc Clin Oncol 16:492a, 1997.*
45. Kelley MC, Bostick P, Bilchik A, **Foshag LJ**, Essner R, Kuo C, Conrad A, Boasberg PD, Hoon DSB. Molecular detection of pancreatic carcinoma (PC) with a multiple marker RT-PCR assay. *Proc Am Soc Clin Oncol 16:293a, 1997.*
46. Hsueh EC, Gupta RK, Gammon G, **Foshag LJ**, Essner R, Qi K, Morton DL. Correlation of specific immune responses with survival in AJCC Stage IV melanoma patients receiving polyvalent melanoma cell vaccine. *Poster Presentation at the American Society for Clinical Oncology, Los Angeles, CA, March 16-19, 1998.*

47. Bilchik AJ, Giuliano A, Essner R, **Foshag LJ**, Keleman P, Stern S, Morton DL. Universal application of intraoperative lymphatic mapping and sentinel node lymphadenectomy in solid neoplasms. *Oral Presentation, American Radium Society, Monte Carlo, May 2-6, 1998.*
48. Hoon DSB, Okamoto T, Wang HJ, Elashoff R, Nizze JA, **Foshag LJ**, Gammon G, Morton DL. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to human leukocyte antigen phenotype of patients? *J Clin Oncol 16(4):1430-1437, 1998.*
49. Bilchik AJ, Giuliano A, Essner R, Bostick P, Keleman P, **Foshag LJ**, Sostrin S, Turner RR, Morton DL. Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. *Cancer J Sci Am 1998;4:351-358.*
50. Hsueh EC, Gupta RK, Gammon G, **Foshag LJ**, Essner R, Qi K, Morton DL. Correlation of specific immune responses with survival in AJCC Stage IV melanoma patients receiving polyvalent melanoma cell vaccine. *Proc Am Soc Clin Oncol 1998;17:435a.*
51. Rose DM, Allegra DP, **Foshag LJ**, Bilchik AJ. Radiofrequency ablation-a novel primary and adjunctive ablative technique for hepatic malignancies. *Oral Presentation, American College of Surgeons, Southern California Chapter, January 22-24, 1999.*
52. Bostick P, Essner R, Glass E, **Foshag L**, Qi K, Haigh P, Morton D. Standardized probe-directed sentinel node dissection in melanoma. *Oral Presentation, Pacific Coast Surgical Association, San Jose del Cabo, Mexico, February 12-16, 1999.*
53. Hsueh EC, Nathanson L, **Foshag LJ**, Essner R, Stern SL, Morton DL. Active specific immunotherapy: a new approach to the management of patients with in-transit melanoma metastases. *Oral Presentation, Society of Surgical Oncology, Orlando, FL, March 4-7, 1999.*
54. Rose DM, Allegra DP, **Foshag LJ**, Bostick PJ, Bilchik AJ. Radiofrequency ablation and intraoperative ultrasound-a novel approach for the management of unresectable hepatic malignancies. *Poster Presentation, Society of Surgical Oncology, Orlando, FL, March 4-7, 1999.*
55. Bilchik AJ, Rose DM, Stern S, **Foshag LJ**, Ramming KP. Prognostic factors and the role of chemotherapy in 153 patients undergoing cryosurgery for unresectable colorectal metastases. *Oral Presentation, World Congress of Surgery, Vienna, Austria, August 15-20, 1999.*

56. Bilchik AJ, Rose DM, Hsueh E, **Foshag LJ**, Morton DL. Cryosurgery and radiofrequency ablation of unresectable malignancies: a proposed algorithm. *Oral Presentation, Western Surgical Association, Santa Fe, NM, November 14-17, 1999.*
57. O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, **Foshag LJ**, Morton DL. Advantages of concurrent biochemotherapy modified by decrescendo Interleukin-2, granulocyte colony-stimulating factor, and Tamoxifen for patients with metastatic melanoma. *J Clin Oncol 1999; 2752-2761.*
58. Keleman PR, Essner R, **Foshag LJ**, Morton DL. Lymphatic mapping and lymphadenectomy after wide local excision of primary melanoma. *J Am Coll Surg 1999; 189:247-252*
59. Essner R, **Foshag LJ**, Glass E, Turner R, Cochran A, Wen DR, Stern S, Wanek L, Elashoff R, Morton DL. Predicting patient survival in early-stage melanoma: results of 712 lymphatic mapping selective node dissections. *Proc Am Soc Clin Oncol 1999;18:529a*
60. Shen P, **Foshag L**, Essner R, Tisman G, Gammon G, Wang H, Elashoff R, Morton D. Post-operative adjuvant therapy using a polyvalent melanoma vaccine improves overall survival of patients with primary melanoma. *Proc Am Soc Clin Oncol 1999;18:533a.*
61. Ollila D, **Foshag LJ**, Essner R, Stern SL, Morton DL. Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma. *Ann Surg Oncol 1999;6:150-154.*
62. DiFronzo LA, Gupta R, Essner R, Wanek L, Stern S, Gammon G, **Foshag L**, Yee R, Leopoldo Z, Morton D. An enhanced humoral immune response predicts improved disease-free and overall survival in AJCC Stage II melanoma patients receiving polyvalent melanoma vaccine (CancerVax). *Proc Am Soc Clin Oncol 1999;18:432a.*
63. Bostick P, Essner R, Glass E, Kelley M, Sarantou T, **Foshag LJ**, Qi K, Morton D. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. *Arch Surg 1999;134:43-49.*
64. Rose DM, Allegra DP, Bostick PJ, **Foshag LJ**, Bilchik AJ. Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies. *Am Surg 1999;65:1009-1014.*

65. Hsueh EC, Nathanson L, **Foshag LJ**, Essner R, Nizze JA, Stern SL, Morton DL. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. *Cancer* 1999;85:2160-2169.
66. Wood T, Rangel D, Hutchinson W, **Foshag L**, Morton D, Bilchik A. Focused examination of sentinel lymph nodes upstages early colorectal carcinoma. *Oral Presentation, American College of Surgeons, Southern California Chapter, Huntington Beach, CA, January 21-23, 2000.*
67. Wood TF, Rose DM, Allegra DP, **Foshag LJ**, Bilchik AJ. Radiofrequency ablation of 174 unresectable hepatic tumors: indications, limitations, and complications. *Society of Surgical Oncology, New Orleans, LA, March 16-19, 2000.*
68. Wood TF, Tsioulis GJ, Saha S, Rangel D, Hutchinson W, **Foshag LJ**, Morton DL, Bilchik AJ. Validation of lymphatic mapping in colorectal cancer: in vivo, ex vivo, and laparoscopic techniques. *Oral Presentation, Society of Surgical Oncology, New Orleans, LA, March 16-19, 2000.*
69. Hsueh EC, **Foshag LJ**, Essner R, Stern SL, Morton DL. Cytoreductive surgery plus adjuvant active specific immunotherapy: a new paradigm for the management of metastatic melanoma. *Oral Presentation, Society of Surgical Oncology, New Orleans, LA, March 16-19, 2000.*
70. Taback B, Fujiwara Y, Nakayama T, Nguyen DH, Wang HJ, **Foshag L**, Morton DL, Hoon DSB. Clinical utility of tumor specific DNA microsatellite markers in plasma of melanoma patients. *Proc Am Assoc Cancer Res* 2000;41:511.
71. Wood TF, Tsioulis GJ, Morton DL, Rangel D, Hutchinson W, **Foshag LJ**, Turner RR, Bilchik AJ. Focused examination of sentinel lymph nodes upstages early colorectal carcinoma. *Am Surg* 2000;66:998-1003.
72. Wood TF, Rose DM, Chung M, Allegra DP, **Foshag LJ**, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indication, limitations, and complications. *Ann Surg Oncol* 2000;7:593-600.
73. Essner R, Bostick PJ, Glass EC, **Foshag LJ**, Haigh PI, Wang JH, Morton DL. Standardized probe-directed sentinel node dissection in melanoma. *Surgery* 2000;127:26-31.
74. Litvak D, Wood T, Tsioulis G, Chung M, Chawla S, **Foshag L**, Ramming K, Morton DL, Bilchik AJ. The results of hepatic cytoreduction plus regional and systemic chemotherapy in 185 patients with unresectable colorectal cancer metastases. *Society of Surgical Oncology, Washington, DC, March 15-18, 2001.*

75. Hsueh EC, Essner R, **Foshag LJ**, Ye W, Morton DL. Reinduction with active specific immunotherapy in recurrent metastatic melanoma. *Oral Presentation, Society of Surgical Oncology, Washington, DC, March 15-18, 2001.*
76. Bleicher RJ, **Foshag LJ**, Essner R, Wanek LA, Morton DL. Sentinel node positivity and characteristics of “thin” invasive cutaneous melanoma. *Society of Surgical Oncology, Washington, DC, March 15-18, 2001.*
77. Chung MH, **Foshag LJ**, Bilchik AJ. Management of incidental gallbladder carcinoma following laparoscopic cholecystectomy. *Contemp Surg 2001;57:506-511.*
78. Morton DL, Hsueh EC, Ollila DW, Essner R, **Foshag LJ**, Stern SL, Ye W. Cytoreductive surgery and adjuvant post-operative immunotherapy with polyvalent melanoma vaccine enhances survival for Stage IV melanoma: results of matched-pair analysis. *Proc Am Soc Clin Oncol 2001;20:355a.*
79. Bilchik AJ, Wood TF, Chawla SP, Rose DM, Chung MH, Stern SL, **Foshag LJ**, Ramming KP. Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. *Clin Colorectal Cancer 2001;1(1):36-42.*
80. Wood TF, Saha S, Morton DL, Tsioulis GJ, Rangel D, Hutchinson W, **Foshag LJ**, Bilchik AJ. Validation of lymphatic mapping in colorectal cancer: in-vivo, ex-vivo, and laparoscopic techniques. *Ann Surg Oncol 2001;8:150-157.*
81. Taback B, Fujiwara Y, Wang HJ, **Foshag LJ**, Morton DL, Hoon DSB. Prognostic significance of circulating microsatellite markers in plasma of melanoma patients. *Cancer Res 2001;61:5723-5726.*
82. Morton DL, Essner R, Hsueh EC, Wang HJ, Wanek LA, **Foshag LJ**, Elashoff R. Prolonged survival of AJCC Stage III melanoma patients receiving post-surgical active immunotherapy with a polyvalent vaccine. *Oral Presentation, American Surgical Association, Hot Springs, VA, April 25-27, 2002.*
83. Hsueh EC, Essner R, **Foshag LJ**, Ye W, Morton DL. Reinduction of active immunotherapy correlates with improved survival in recurrent metastatic melanoma. *Proc Am Soc Clin Oncol 2002;21:10b.*
84. Trocha SD, Hsueh EC, Essner R, **Foshag LJ**, O’Day S, Wanek L, Morton DL. Prolonged survival of 231 patients with AJCC Stage IV melanoma receiving active specific immunotherapy with a polyvalent vaccine. *Proc Am Soc Clin Oncol 2002;21:31a.*

85. Bleicher RJ, Allegra DP, Nora DT, Wood TF, **Foshag LJ**, Bilchik AJ. Radiofrequency ablation in 406 complex unresectable liver tumors: lessons learned. *Ann Surg Oncol* 2002;9(1):S8.
86. Yao KA, Hsueh EC, Essner R, **Foshag L**, Wanek L, Morton DL. Is sentinel lymph node mapping indicated for intransit malignant melanoma? *Ann Surg Oncol* 2002;9(1):S80.
87. DiFronzo LA, Gupta RK, Essner R, **Foshag LJ**, O'Day SJ, Wanek LA, Stern SL, Morton DL. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer Stage II melanoma patients receiving adjuvant polyvalent vaccine. *J Clin Oncol* 2002;20:3242-3248.
88. Yao K, Hsueh EC, Essner R, **Foshag LJ**, Wanek L, Morton D. Effectiveness of sentinel lymph node dissection in regional intransit melanoma recurrence to identify occult regional nodal metastases. *Proc Am Soc Clin Oncol* 2002;21:342a.
89. Hsueh EC, Essner R, **Foshag LJ**, Ye W, Morton DL. Active immunotherapy by reinduction with a polyvalent allogenic cell vaccine correlates with improved survival in recurrent metastatic melanoma. *Ann Surg Oncol* 2002;9:486-492.
90. Morton DL, Hsueh EC, Essner R, **Foshag LJ**, O'Day SJ, Bilchik A, Gupta RK, Hoon DSB, Ravindranath M, Nizze JA, Gammon G, Wanek LA, Wang HJ, Elashoff RM. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. *Ann Surg* 2002;236:438-449.
91. Litvak DA, Wood TF, Tsioulis GJ, Chung M, Chawla SP, **Foshag LJ**, Morton DL, Ramming KP, Bilchik AJ. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. *Ann Surg Oncol* 2002;9:148-155.
92. Bleicher RJ, Essner R, **Foshag LJ**, Wanek LA, Morton DL. The role of sentinel lymphadenectomy in thin cutaneous melanomas. *Proc Am Soc Clin Oncol* 2002;21:339a.
93. Hsueh EC, **Foshag L**, Essner R, Ye X, Morton DL. Prolonged survival after complete resection of metastases from intraocular melanoma. *Poster Presentation, Society of Surgical Oncology, Los Angeles, CA, March 6-9, 2003.*
94. Morton DL, Wen DR, **Foshag LJ**, Essner R, Cochran A. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and neck. *J Clin Oncol Classic Papers Current Comments, In Press.*

95. Hsueh EC, Essner R, **Foshag LJ**, Ollila DW, Gammon G, O'Day SJ, Boasberg PB, Stern SL, Ye X, Morton DL. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. *J Clin Oncol, In Press.*
96. Bleicher RJ, Allegra DP, Nora DT, Wood TF, **Foshag LJ**, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. *Ann Surg Oncol, In Press.*

BOOK CHAPTERS

1. **Foshag LJ**, Watne A. Head and Neck Nodules. In: *James E(ed): Principals of Basic Surgical Practice, Hanley & Belfus, Inc. Philadelphia, 1989, pp 131-142.*
2. Morton DL, Hoon DSB, Gupta RG, Nizze JA, Famatiga E, **Foshag LJ**, Furatani S, Irie RK. Treatment of Malignant Melanoma by Active Specific Immunotherapy in Combination with Biological Response Modifiers. In: *Torisu M, Yoshida T (eds.) New Horizons of Tumor Immunotherapy, Elsevier Science Publishers B.V. (Biomedical division). 1989, pp 665-683.*
3. Morton DL, Hoon DSB, Gupta RK, Nizze JA, **Foshag LJ**, Irie RF. Active Specific Immunotherapy for Malignant Melanoma. In: *Cutaneous Melanoma, Second Edition. Eds. Balch CM, Houghton An, Milton GW, Sober AJ, Soong SJ. JB Lippincott Company. 1992, pp 544-546.*
4. Morton DL, Wen DR, **Foshag LJ**, Cochran AJ. Use of intraoperative lymphatic mapping and selective lymphadenectomy to identify candidates for adjuvant therapy of melanoma. In: *Adjuvant Therapy of Cancer, edited by Salmon SE. JB Lippincott, Philadelphia, 1993, pp 393-397.*
5. Morton DL, Nizze JA, Hoon DSB, **Foshag LJ**, Famatiga E, Gupta RK, Irie RF, Ramming KP. Improved survival of metastatic melanoma patients receiving active specific immunotherapy with a polyvalent whole-cell vaccine. In: *Adjuvant Therapy of Cancer, edited by Salmon SE. JB Lippincott, Philadelphia, 1993, pp398-404.*

INVITED LECTURES (1989-PRESENT)

1. Department of Surgery Grand Rounds: *UCLA School of Medicine, Los Angeles, California, November 8, 1989.*
2. Surgical Oncology Research Conference: *UCLA School of Medicine, Los Angeles, California, December 1989.*

3. Cancer Support Group: *UCLA Medical Center, Los Angeles, California, March 1991.*
4. Principals of Surgical Intervention: *Nurses Oncology Education Program, Saint John's Health Center, Santa Monica, California, January 21, 1992.*
5. Liver and Pancreas Cancer: *Nurses Oncology Education Program, Saint John's Health Center, Santa Monica, California, January 28, 1992.*
6. Melanoma Vaccine Therapy: *Dermatology Grand Rounds, Loma Linda University, Loma Linda, California, June 4, 1993.*
7. New Modalities in the Diagnosis, Treatment, and Management of Hepatic Carcinoma. *Saint John's Health Center, Santa Monica, California, June 26, 1993.*
8. New Technology, Cryosurgery of the Liver. *Kaiser Permanente Medical Center, Los Angeles, California, October 16, 1993.*
9. Breast Cancer Prevention and Detection: *Estee Lauder Companies, Origins at Century City, Los Angeles, California, October 12, 1994.*
10. Present Status of Lymph Node Dissection in the Treatment of Early Stage Melanoma: Surgical Oncology Update-Melanoma and Skin Cancer: *University of Crete Medical School, Department of Surgical Oncology, Crete, Greece, October 7, 1994.*
11. Update on the Treatment of Melanoma: *Dermatology Grand Rounds, Loma Linda University, Loma Linda, California, May 5, 1995.*
12. Forum on Current Concepts of Cancer: *John Wayne Cancer Institute (Community Service) Santa Monica, California, August 1995.*
13. Current Management of Primary Melanoma: *Downey Medical Center, Downey, California, October 1996.*
14. Skin Cancer: *Department of Water & Power (Community Service), Wilmington, California, 1996.*
15. Department of Dermatology Grand Rounds: *Loma Linda University, Loma Linda, California, January 1997.*
16. The Breast Cancer Community Conference: "The Sentinel Node and its Role in the Management of Breast Cancer": *American Cancer Society/Good Samaritan Hospital, Los Angeles, California October 22, 1999.*

17. The Great Cancer Round-up, Detection and Prevention: “Prevention and Screening of Melanoma”: *Good Samaritan Hospital, Los Angeles, California June 30, 2001.*
18. Melanoma for General Surgeons: “Novel (Neoadjuvant) Approaches to Complex Regional and Metastatic Disease”: *American College of Surgeons 30th Spring Meeting, San Diego, California, April 14-17, 2002.*
19. Career Days at Will Rogers Elementary School (Community Service), Santa Monica, California, June 10, 2002.
20. Melanoma for General Surgeons: “Novel (Neoadjuvant) Approaches to Complex Regional and Metastatic Disease”: *Department of General Surgery Grand Rounds, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, December 17, 2002.*

LJF/CV/2004